Advances in prognostic factors for anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis

ZHANG Cen; BAI Ling; LI Feifei; ZHAO Peipei; ZHUO Cui; MA Wenlan; ZHANG Sigong

doi:10.16766/j.cnki.issn.1674-4152.003727

Volume 22 Issue 10

Oct. 2024

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2024 > 22(10): 1755-1760

ZHANG Cen, BAI Ling, LI Feifei, ZHAO Peipei, ZHUO Cui, MA Wenlan, ZHANG Sigong. Advances in prognostic factors for anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis[J]. Chinese Journal of General Practice, 2024, 22(10): 1755-1760. doi: 10.16766/j.cnki.issn.1674-4152.003727

Citation:

ZHANG Cen, BAI Ling, LI Feifei, ZHAO Peipei, ZHUO Cui, MA Wenlan, ZHANG Sigong. Advances in prognostic factors for anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis[J]. Chinese Journal of General Practice, 2024, 22(10): 1755-1760. doi: 10.16766/j.cnki.issn.1674-4152.003727

Citation:

ZHANG Cen, BAI Ling, LI Feifei, ZHAO Peipei, ZHUO Cui, MA Wenlan, ZHANG Sigong. Advances in prognostic factors for anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis[J]. Chinese Journal of General Practice, 2024, 22(10): 1755-1760. doi: 10.16766/j.cnki.issn.1674-4152.003727

PDF( 475 KB)

Advances in prognostic factors for anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis

doi: 10.16766/j.cnki.issn.1674-4152.003727

ZHANG Cen¹
, BAI Ling¹
, LI Feifei¹
, ZHAO Peipei¹
, ZHUO Cui¹
, MA Wenlan²
, ZHANG Sigong^{3
,
,}

1.
The Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, China

Funds:

82060302

82260325

lzuyxcx-2022-168

CY2021-MS-A04

CYXZ2021-47

Received Date: 2024-01-23
Available Online: 2024-12-28

Abstract

Abstract

Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis is a special subtype of idiopathic inflammatory myopathies, mainly characterized by dermatomyositis-specific skin lesions and interstitial lung disease. It is prone to rapidly progressive interstitial lung disease with a significantly high 6-month mortality rate. Besides, there is a great difference in prognosis among individuals. Therefore, early assessment of prognosis is crucial for the development of individualized diagnosis and therapeutic strategies. Available research suggests that several factors are associated with poor prognosis in anti-melanoma differentiation-related gene 5 antibody-positive dermatomyositis, including advanced age at onset, male gender, smoking, fever, dyspnea, pleural effusion, high titer of anti-melanoma differentiation-associated gene 5 antibodies, positive IgG1 subtype of anti-melanoma differentiation-associated gene 5 antibodies, positive anti-Ro-52 antibodies, elevated inflammatory markers (such as serum C-reactive protein, lactate dehydrogenase, and creatine kinase), elevated lung injury markers (such as serum Krebs von den Lungen-6), elevated markers of macrophage activation (such as serum ferritin), decreased peripheral blood lymphocyte counts, decreased oxygenation index, and a lower percentage of the predicted value for fprced vital capacity. The prognosis tends to be better for patients with a longer course of disease and joint symptoms. In addition, some scholars have constructed risk prediction models based on these prognostic factors. However, the existing models are relatively limited. More comprehensive and reliable risk prediction models need to be further developed and verified. Currently, effective treatments for anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis are lacking. For patients at high risk of death, early treatment with triple therapy, comprising high-dose glucocorticoids, Janus kinase inhibitors, rituximab, plasma exchange, and prophylactic use of cotrimoxazole/metronidazole, shows promise for improving prognosis.
- Anti-melanoma differentiation-associated gene 5 antibody,
- Dermatomyositis,
- Prognostic factors

FullText(HTML)

References(49)

References

[1]	LUNDBERG I E, FUJIMOTO M, VENCOVSKY J, et al. Idiopathic inflammatory myopathies[J]. Nat Rev Dis Primers, 2021, 7(1): 86. DOI: 10.1038/s41572-021-00321-x.
[2]	朱利君, 杨闵, 王英, 等. 皮肌炎合并视神经脊髓炎谱系疾病1例[J]. 四川医学, 2023, 44(1): 108-110. ZHU L J, YANG M, WANG Y, et al. Dermatomyositis combined with neuromyelitis optica spectrum disorders: a case report[J]. Sichuan Medical Journal, 2023, 44(1): 108-110.
[3]	杨翰清, 罗凤鸣. 抗黑色素瘤分化相关基因5抗体阳性皮肌炎患者间质性肺疾病的诊治进展[J]. 华西医学, 2021, 36(1): 120-124. YANG H Q, LUO F M. Progress in diagnosis and treatment of interstitial lung disease in patients with melanoma differentiation-associated gene 5 antibody-positive dermatomyositis[J]. West China Medicine, 2021, 36(1): 120-124.
[4]	WU W, GUO L, FU Y, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis[J]. Clin Rev Allergy Immunol, 2021, 60(2): 293-304. doi: 10.1007/s12016-020-08822-5
[5]	SO J, SO H, WONG V T, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis[J]. Rheumatology (Oxford), 2022, 61(11): 4437-4444. doi: 10.1093/rheumatology/keac094
[6]	邹如意, 赵琪, 田亚琼, 等. 抗黑色素瘤分化相关基因5阳性的皮肌炎相关间质性肺疾病患者的临床特征和预后因素分析[J]. 中华结核和呼吸杂志, 2023, 46(8): 781-790. ZOU R Y, ZHAO Q, TIAN Y Q, et al. Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease[J]. Chinese Journal of Tuberculosis and Respiratory, 2023, 46(8): 781-790.
[7]	ZHAO S, MA X, ZHANG X, et al. Clinical significance of HScore and MS score comparison in the prognostic evaluation of anti-MDA5-positive patients with dermatomyositis and interstitial lung disease[J]. Mod Rheumatol, 2022, 32(2): 373-379. doi: 10.1093/mr/roab017
[8]	LIU T, LI W, ZHANG Z, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis[J]. BMC Pulm Med, 2022, 32(2): 373-379.
[9]	NIU Q, ZHAO L Q, MA W L, et al. A new predictive model for the prognosis of MDA5⁺DM-ILD[J]. Front Med (Lausanne), 2022, 9: 908365. DOI: 10.3389/fmed.2022.908365.
[10]	WANG C, DU J, MEI X, et al. The value of effective lung ventilation area ratio based on ct image analysis is a new index to predict the shorter outcome of anti-melanoma differentiation-associated protein 5 positive dermatomyositis associated interstitial lung disease: a single-center retrospective study[J]. Front Med (Lausanne), 2021, 8: 728487. DOI: 10.3389/fmed.2021.728487.
[11]	LI Y, DENG W, ZHOU Y, et al. A nomogram based on clinical factors and CT radiomics for predicting anti-MDA5⁺DM complicated by RP-ILD[J]. Rheumatology(Oxford), 2024, 63(3): 809-816. doi: 10.1093/rheumatology/kead263
[12]	YOU H, WANG L, WANG J, et al. Time-dependent changes in RPILD and mortality risk in anti-MDA5⁺DM patients: a cohort study of 272 cases in China[J]. Rheumatology (Oxford), 2023, 62(3): 1216-1226. doi: 10.1093/rheumatology/keac450
[13]	CHEN M, ZHAO Q, DIAO L, et al. Distribution of anti-melanoma differentiation associated gene 5 (MDA5) IgG subclasses in MDA5⁺dermatomyositis[J]. Rheumatology (Oxford), 2021, 61(1): 430-439. doi: 10.1093/rheumatology/keab268
[14]	XU Y T, ZHANG Y M, YANG H X, et al. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease[J]. Rheumatology(Oxford), 2022, 62(1): 397-406. doi: 10.1093/rheumatology/keac229
[15]	DUNGA S K, KAVADICHANDA C, GUPTA L, et al. Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study[J]. Rheumatol Int, 2022, 42(7): 1155-1165. doi: 10.1007/s00296-021-04897-1
[16]	GUI X, SHENYUN S, DING H, et al. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease[J]. Rheumatology(Oxford), 2022, 61(11): 4570-4578. doi: 10.1093/rheumatology/keac090
[17]	LIU L, ZHANG Y, WANG C, et al. Ground-glass opacity score predicts the prognosis of anti-MDA5 positive dermatomyositis: a single-centre cohort study[J]. Orphanet J Rare Dis, 2023, 18(1): 208. DOI: 10.1186/s13023-023-02827-x.
[18]	ZUO Y, YE L, CHEN F, et al. Different multivariable risk factors for rapid progressive interstitial lung disease in Anti-MDA5 positive dermatomyositis and anti-synthetase syndrome[J]. Front Immunol, 2022, 13: 845988. DOI: 10.3389/fimmu.2022.845988.
[19]	LI M, ZHAO X, LIU B, et al. Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis[J]. Front Immunol, 2023, 14: 1209282. DOI: 10.3389/fimmu.2023.1209282.
[20]	ZHU Y, WANG L, SUN Y, et al. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease[J]. Clin Exp Rheumatol, 2022, 40(2): 292-297. doi: 10.55563/clinexprheumatol/zmn18h
[21]	GUI X, MA M, DING J, et al. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis[J]. Rheumatology (Oxford), 2021, 60(8): 3913-3922. doi: 10.1093/rheumatology/keaa843
[22]	LYU W, ZHOU Y, ZHUANG Y, et al. Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease[J]. Clin Exp Rheumatol, 2020, 38(6): 1068-1074.
[23]	HE X, JI J, CHEN X, et al. Serum ferritin as a significant biomarker for patients with idiopathic inflammatory myopathy-associated interstitial lung disease: a systematic review and meta-analysis[J]. Semin Arthritis Rheum, 2024, 64: 152350. DOI: 10.1016/j.semarthrit.2023.152350.
[24]	GAO Y, ZHAO Q, XIE M, et al. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease[J]. Cytokine, 2020, 135: 155209. DOI: 10.1016/j.cyto.2020.155209.
[25]	HORIIKE Y, SUZUKI Y, FUJISAWA T, et al. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD[J]. Rheumatology (Oxford), 2019, 58(12): 2143-2152. doi: 10.1093/rheumatology/kez185
[26]	PENG Q L, ZHANG Y M, LIANG L, et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis[J]. Clin Exp Immunol, 2020, 199(3): 314-325. doi: 10.1111/cei.13404
[27]	FUJISAWA T, HOZUMI H, YASUI H, et al. Clinical significance of serum chitotriosidase level in Anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease[J]. J Rheumatol, 2019, 46(8): 935-942. http://www.zhangqiaokeyan.com/journal-foreign-detail/0704020449979.html
[28]	JIANG L, WANG Y, PENG Q, et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody[J]. Clin Rheumatol, 2019, 38(6): 1655-1663.
[29]	HUANG W, CHEN D, WANG Z, et al. Evaluating the value of superoxide dismutase in anti-MDA5-positive dermatomyositis associated with interstitial lung disease[J]. Rheumatology (Oxford), 2023, 62(3): 1197-1203.
[30]	LIANG L, ZHANG Y M, SHEN Y W, et al. Aberrantly expressed Galectin-9 is involved in the immunopathogenesis of Anti-MDA5-Positive dermatomyositis-associated interstitial lung disease[J]. Front Cell Dev Biol, 2021, 9: 628128. DOI: 10.3389/fcell.2021.628128.
[31]	JIN Q, FU L, YANG H, et al. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis[J]. J Intern Med, 2023, 293(4): 494-507.
[32]	LIN S, ZHANG Y, CAO Z, et al. Decrease in cell counts and alteration of phenotype characterize peripheral NK cells of patients with anti-MDA5-positive dermatomyositis[J]. Clin Chim Acta, 2023, 543: 117321. DOI: 10.1016/j.cca.2023.117321.
[33]	WANG K, ZHAO J, CHEN Z, et al. CD4⁺CXCR4⁺ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease[J]. Rheumatology (Oxford), 2019, 58(3): 511-521.
[34]	WU W, XU W, SUN W, et al. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study[J]. Rheumatology (Oxford), 2021, 61(1): 230-239.
[35]	MINOIA F, BOVIS F, DAVI S, et al. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2019, 78(10): 1357-1362. http://www.xueshufan.com/publication/2961584204
[36]	GONO T, MASUI K, NISHINA N, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis/dermatomyositis-associated interstitial lung disease[J]. Arthritis Rheumatol, 2021, 73(4): 677-686.
[37]	GUI X, LI W, YU Y, et al. Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease[J]. Front Immunol, 2022, 13: 978708. DOI: 10.3389/fimmu.2022.978708.
[38]	XU W, WU W, ZHANG D, et al. A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis[J]. Sci Rep, 2021, 11(1): 17070. DOI: 10.1038/s41598-021-96292-w.
[39]	LIAN X, ZOU J, GUO Q, et al. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the flair model[J]. Chest, 2020, 158(4): 1535-1545.
[40]	LI Y, LI Y, WANG Y, et al. A clinical risk model to predict rapidly progressive interstitial lung disease incidence in dermatomyositis[J]. Front Med (Lausanne), 2021, 8: 733599. DOI: 10.3389/fmed.2021.733599.
[41]	张玉慧, 宋为民, 李志军. 特发性炎性肌病的诊断与治疗[J]. 中华全科医学, 2020, 18(7): 1073-1074. https://kns.cnki.net/kcms2/article/abstract?v=ZZIl2iqmIcQc7dRQOA8JZV8_ZUeC0nqRzpJAq3Mim8hcl1uQUp82u0cfTrYw61R7Bm6tIRL1osubszRCzykSV_HkvE6KbMZR0s0IzswvIfkylYTOKy50jTTbV2lPFIkTXDXFnaBVG2iBO_3wrFlJBXpGulz0bdK3XHkXiKoIOWlOenIymVQAVAbYX_llNDiJ&uniplatform=NZKPT&language=CHS ZHANG Y H, SONG W M, LI Z J, et al. Diagnosis and treatment of idiopathic inflammatory myopathy[J]. Chinese Journal of General Practice, 2020, 18(7): 1073-1074. https://kns.cnki.net/kcms2/article/abstract?v=ZZIl2iqmIcQc7dRQOA8JZV8_ZUeC0nqRzpJAq3Mim8hcl1uQUp82u0cfTrYw61R7Bm6tIRL1osubszRCzykSV_HkvE6KbMZR0s0IzswvIfkylYTOKy50jTTbV2lPFIkTXDXFnaBVG2iBO_3wrFlJBXpGulz0bdK3XHkXiKoIOWlOenIymVQAVAbYX_llNDiJ&uniplatform=NZKPT&language=CHS
[42]	TSUJI H, NAKASHIMA R, HOSONO Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis[J]. Arthritis Rheumatol, 2020, 72(3): 488-498.
[43]	CHEN Z, WANG X, YE S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease[J]. N Engl J Med, 2019, 381(3): 291-293. http://www.xueshufan.com/publication/2961094118
[44]	IDA T, FURUTA S, TAKAYAMA A, et al. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis[J]. RMD Open, 2023, 9(1): e002795. DOI: 10.1136/rmdopen-2022-002795.
[45]	AGGARWAL R, CHARLES-SCHOEMAN C, SCHESSL J, et al. Trial of intravenous immune globulin in dermatomyositis[J]. N Engl J Med, 2022, 387(14): 1264-1278. http://pubmed.ncbi.nlm.nih.gov/36599069/
[46]	GE Y, LI S, TIAN X, et al. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy[J]. Clin Rheumatol, 2021, 40(6): 2311-2317.
[47]	BAY P, DE CHAMBRUN M P, ROTHSTEIN V, et al. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease[J]. J Autoimmun, 2022, 59(11): 3284-3292.
[48]	SHIRAKASHI M, NAKASHIMA R, TSUJI H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment[J]. Rheumatology (Oxford), 2020, 59(11): 3284-3292. http://www.zhangqiaokeyan.com/journal-foreign-detail/0704028913579.html
[49]	LIU L, ZHANG Y, LIU S, et al. Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5[J]. Rheumatology (Oxford), 2023, 62(9): 3095-3100.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (43) PDF downloads(3)

Advances in prognostic factors for anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis

doi: 10.16766/j.cnki.issn.1674-4152.003727

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Advances in prognostic factors for anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis

doi: 10.16766/j.cnki.issn.1674-4152.003727

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content